natgillin/translations-raw huggingface dataset:
vincristine, vinblastine and other “vinca alkaloids” (used to treat cancer)
vinkristin, vinblastin i drugi vinka alkaloidi (primjenjuju se za liječenje raka),
vincristine, vinblastine, used for cancer, mycophenolate mofetil (MMF), used in transplant patients,
vinkristin, vinblastin, za liječenje raka, mofetilmikofenolat (MMF), za bolesnike kojima je obavljena transplantacija,
Vinflunine clearance was significantly decreased in patients ≥ 80 years old as compared to a control group of younger patients < 70 years.
Klirens vinflunina značajno se smanjio u bolesnika u dobi od 80 i više godina u usporedbi s kontrolnom skupinom bolesnika mlañih od 70 godina.
Vinflunine doses were adjusted according to 3 age groups as shown below:
Doze vinflunina bile su prilagoñene prema 3 dobne skupine kako je prikazano u nastavku:
Vinflunine is eliminated following a multi-exponential concentration decay, with a terminal half-life (t1/2) close to 40 h.
Vinflunin se eliminira nakon multieksponencijalnog pada koncentracije, s terminalnim poluvremenom (t½) blizu 40 h.
Vinflunine is moderately bound to human plasma proteins (67.2±1.1%) with a ratio between plasma and whole blood concentrations of 0.800.12.
Vinflunin se umjereno veže za bjelančevine ljudske plazme (67,2±1,1%) pri čemu je omjer izmeñu koncentracija u plazmi i cijeloj krvi 0,800,12.
Vinflunine pharmacokinetics was not modified in those patients, however based on hepatic biologic parameter modifications following vinflunine administration (gamma glutamyl transferases (GGT), transaminases, bilirubin), the dose recommendations are as follows:
Farmakokinetika vinflunina nije promijenjena u tih bolesnika, meñutim, na temelju promjena jetrenih bioloških parametara nakon primjene vinflunina (gama-glutamil-transferaze (GGT), transaminaza, bilirubina), preporučuju se sljedeće doze:
Violent shaking (seizures) and loss of consciousness;
ilovito tresenje (napadaji) i gubitak svijesti;
Violent, uncontrollable muscular contractions often accompanied by unconsciousness that can be due to an epileptic attack (seizures).
Jako, nekontrolirano grčenje mišića, često popraćeno nesvjesticom, koje može biti uzrokovano epileptičkim napadajem.
Violet
ljubičasta
Violet white, biconvex, ovaloid film-coated tablet imprinted with “CVI” on one side and “NVR” on the other.
Ljubičasto-bijela, bikonveksna, ovalna filmom obložena tableta, s utisnutom oznakom „CVI“ na jednoj i „NVR“ na drugoj strani.
Vipdomet 12.5 mg/1000 mg film-coated tablets
Vipdomet 12,5 mg/1000 mg filmom obložene tablete
Vipdomet 12.5 mg/1000 mg film-coated tablets alogliptin/metformin hydrochloride
Vipdomet 12,5 mg/1000 mg filmom obložene tablete alogliptin/metforminklorid
Vipdomet 12.5 mg/1000 mg tablets alogliptin/metformin hydrochloride
Vipdomet 12,5 mg/1000 mg tablete alogliptin/metforminklorid
Vipdomet 12.5 mg/850 mg film-coated tablets
Vipdomet 12,5 mg/850 mg filmom obložene tablete
Vipdomet 12.5 mg/850 mg film-coated tablets alogliptin/metformin hydrochloride
Vipdomet 12,5 mg/850 mg filmom obložene tablete alogliptin/metforminklorid
Vipdomet 12.5 mg/850 mg film-coated tablets Vipdomet 12.5 mg/1000 mg film-coated tablets Alogliptin/Metformin hydrochloride
Vipdomet 12,5 mg/850 mg filmom obložene tablete Vipdomet 12,5 mg/1000 mg filmom obložene tablete alogliptin/metforminklorid
Vipdomet 12.5 mg/850 mg tablets alogliptin/metformin hydrochloride
Vipdomet 12,5 mg/850 mg tablete alogliptin/metforminklorid
Vipdomet combines two antihyperglycaemic medications with complementary and distinct mechanisms of action to improve glycaemic control in patients with type 2 diabetes mellitus: alogliptin, a dipeptidyl-peptidase-4 (DPP-4) inhibitor, and metformin, a member of the biguanide class.
Vipdomet sadrži dva antihiperglikemijska lijeka koji komplementarnim i različitim mehanizmom djelovanja poboljšavaju kontrolu glikemije u bolesnika sa šećernom bolešću tipa 2: alogliptin, inhibitor dipeptidil-peptidaze-4 (DPP4) i metformin, predstavnik klase bigvanida.
Vipdomet contains two different medicines called alogliptin and metformin in one tablet:
Vipdomet sadrži dvije različite djelatne tvari alogliptin i metformin u jednoj tableti:
Vipdomet is available in blister packs containing 10, 14, 20, 28, 56, 60, 98, 112, 120, 180, 196, 196 (2x98 multipack) or 200 tablets.
Vipdomet je dostupan u blister pakiranjima koja sadrže 10, 14, 20, 28, 56, 60, 98, 112, 120, 180, 196, 196 (2x98 višestruko pakiranje) ili 200 tableta.
Vipdomet is not recommended for use in patients with moderate and severe renal impairment and end-stage renal disease (creatinine clearance < 60 mL/min)(see section 4.3).
Vipdomet se ne preporučuje za primjenu bolesnicima s umjerenim i teškim oštećenjem bubrega i završnim stadijem bolesti bubrega (klirens kreatinina < 60 ml/min) (vidjeti dio 4.3).
Vipdomet is used to lower blood sugar levels in adults with type 2 diabetes.
Vipdomet je koristi za snižavanje razina šećera u krvi u odraslih bolesnika sa šećernom bolešću tipa 2.
Vipdomet should be taken twice daily because of the pharmacokinetics of its metformin component.
Vipdomet treba uzimati dvaput na dan zbog farmakokinetike sadržanog metformina.
Vipdomet should not be used in patients with hepatic impairment (see section 4.2).
Vipdomet se ne smije primjenjivati u bolesnika s oštećenjem jetre (vidjeti dio 4.2).
Vipdomet should not be used in patients with hepatic impairment (see sections 4.3 and 5.2).
Vipdomet se ne smije primjenjivati u bolesnika s oštećenjem jetre (vidjeti dijelove 4.3 i 5.2).
Vipidia 12.5 mg film-coated tablets alogliptin
Vipidia 12,5 mg filmom obložene tablete alogliptin
Vipidia 12.5 mg tablets alogliptin
Vipidia 12,5 mg tablete alogliptin
Vipidia 25 mg film-coated tablets alogliptin
Vipidia 25 mg filmom obložene tablete alogliptin
Vipidia 25 mg film-coated tablets Vipidia 12.5 mg film-coated tablets Vipidia 6.25 mg film-coated tablets Alogliptin
Vipidia 25 mg filmom obložene tablete Vipidia 12,5 mg filmom obložene tablete Vipidia 6,25 mg filmom obložene tablete alogliptin
Vipidia 25 mg tablets alogliptin
Vipidia 25 mg tablete alogliptin
Vipidia 6.25 mg film-coated tablets (tablets) are light pink, oval (approximately 9.1 mm long by
Vipidia 6,25 mg filmom obložene tablete (tablete) su svijetlo ružičaste, ovalne (otprilike 9,1 mm duge i 5,1 mm široke), bikonveksne filmom obložene tablete s oznakom „TAK“ i
Vipidia 6.25 mg film-coated tablets alogliptin
Vipidia 6,25 mg filmom obložene tablete alogliptin
Vipidia 6.25 mg tablets alogliptin
Vipidia 6,25 mg tablete alogliptin
Vipidia contains the active substance alogliptin which belongs to a group of medicines called “oral anti-diabetics”.
Vipidia sadrži djelatnu tvar alogliptin koja pripada skupini lijekova koji se zovu „oralni antidijabetici“.
Vipidia has been studied in seven main studies involving 5,675 adults with type 2 diabetes.
Lijek Vipidia ispitan je u sedam glavnih ispitivanja koja su obuhvatile 5.675 odraslih osoba sa šećernom bolešću tipa 2.
Vipidia should not be used during pregnancy or breast-feeding unless your doctor thinks it is clearly necessary.
Vipidia se ne smije koristiti tijekom trudnoće ili dojenja osim ako liječnik smatra da je to nužno neophodno.
vir/ritona
(0,85-0,99)
vir/ritona
tonavir
vir/ritona vir
tonavir
ViraferonPeg (1.5 micrograms/kg/week for one month followed by 0.5 microgram/kg/week for 11 months) + ribavirin (1,000/1,200 mg/day), (n = 514).
ViraferonPeg (1,5 mikrograma/kg na tjedan tijekom mjesec dana, a zatim 0,5 mikrograma/kg na tjedan tijekom preostalih 11 mjeseci) + ribavirin (1000/1200 mg na dan), (n=514). interferon alfa-2b (3 mil.
ViraferonPeg (1.5 micrograms/kg/week) + ribavirin (800 mg/day), (n = 511).
ViraferonPeg (1,5 mikrograma/kg na tjedan) + ribavirin (800 mg na dan), (n=511).
ViraferonPeg 1.5 g/kg once weekly plus Ribavirin 800-1,400 mg/day
ViraferonPeg 1,5 μg/kg jedanput na tjedan + ribavirin 800-1400 mg/dan
ViraferonPeg 100 micrograms powder and solvent for solution for injection
ViraferonPeg 100 mikrograma prašak i otapalo za otopinu za injekciju
ViraferonPeg 100 micrograms powder and solvent for solution for injection in pre-filled pen
ViraferonPeg 100 mikrograma prašak i otapalo za otopinu za injekciju u napunjenoj brizgalici
ViraferonPeg 100 micrograms powder and solvent for solution for injection peginterferon alfa-2b
ViraferonPeg 100 mikrograma prašak i otapalo za otopinu za injekciju peginterferon alfa-2b
ViraferonPeg 120 micrograms is available in different pack sizes:
ViraferonPeg je dostupan u različitim veličinama pakiranja:
ViraferonPeg 120 micrograms powder and solvent for solution for injection
ViraferonPeg 120 mikrograma prašak i otapalo za otopinu za injekciju
ViraferonPeg 120 micrograms powder and solvent for solution for injection in pre-filled pen
ViraferonPeg 120 mikrograma prašak i otapalo za otopinu za injekciju u napunjenoj brizgalici
ViraferonPeg 120 micrograms powder and solvent for solution for injection peginterferon alfa-2b
ViraferonPeg 120 mikrograma prašak i otapalo za otopinu za injekciju peginterferon alfa-2b
ViraferonPeg 150 micrograms powder and solvent for solution for injection
ViraferonPeg 150 mikrograma prašak i otapalo za otopinu za injekciju
ViraferonPeg 150 micrograms powder and solvent for solution for injection in pre-filled pen
ViraferonPeg 150 mikrograma prašak i otapalo za otopinu za injekciju u napunjenoj brizgalici
ViraferonPeg 150 micrograms powder and solvent for solution for injection peginterferon alfa-2b
ViraferonPeg 150 mikrograma prašak i otapalo za otopinu za injekciju peginterferon alfa-2b
ViraferonPeg 50 micrograms powder and solvent for solution for injection
ViraferonPeg 50 mikrograma prašak i otapalo za otopinu za injekciju
ViraferonPeg 50 micrograms powder and solvent for solution for injection in pre-filled pen
ViraferonPeg 50 mikrograma prašak i otapalo za otopinu za injekciju u napunjenoj brizgalici
ViraferonPeg 50 micrograms powder and solvent for solution for injection peginterferon alfa-2b
ViraferonPeg 50 mikrograma prašak i otapalo za otopinu za injekciju peginterferon alfa-2b
ViraferonPeg 50 micrograms – vial of powder
ViraferonPeg 50 mikrograma - bočica s praškom
ViraferonPeg 80 micrograms powder and solvent for solution for injection
ViraferonPeg 80 mikrograma prašak i otapalo za otopinu za injekciju
ViraferonPeg 80 micrograms powder and solvent for solution for injection in pre-filled pen
ViraferonPeg 80 mikrograma prašak i otapalo za otopinu za injekciju u napunjenoj brizgalici
ViraferonPeg 80 micrograms powder and solvent for solution for injection peginterferon alfa-2b
ViraferonPeg 80 mikrograma prašak i otapalo za otopinu za injekciju peginterferon alfa-2b
ViraferonPeg can be used in combination with ribavirin in paediatric patients 3 years of age and older.
ViraferonPeg se u kombinaciji s ribavirinom može primjenjivati u pedijatrijskih bolesnika u dobi od 3 i više godina.
ViraferonPeg combination therapy (bitherapy or tritherapy)
ViraferonPeg u kombiniranoj terapiji (dvojnoj ili trojnoj)
ViraferonPeg contains sucrose.
ViraferonPeg sadrži saharozu
ViraferonPeg For adult patients who use 0.5 g/kg ViraferonPeg monotherapy, dose reduction may be accomplished by reducing the prescribed volume by one-half as shown in Table 3b.
U odraslih bolesnika koji primaju ViraferonPeg u monoterapiji u dozi od 0,5 µg/kg smanjenje doze može se postići smanjenjem propisanog volumena za polovicu, kako je prikazano u Tablici 3b.
ViraferonPeg is available in different pack sizes:
ViraferonPeg je dostupan u različitim veličinama pakiranja:
ViraferonPeg is likely to also cause this effect.
ViraferonPeg bi vjerojatno imao isti učinak.
ViraferonPeg is recommended for use in fertile women only when they are using effective contraception during the treatment.
Primjena lijeka ViraferonPeg u plodnih žena preporučuje se samo ako tijekom liječenja koriste učinkovitu kontracepciju.
ViraferonPeg is supplied as:
ViraferonPeg je dostupan u pakiranjima koja sadrže:
ViraferonPeg monotherapy
ViraferonPeg u monoterapiji
ViraferonPeg monotherapy was not studied in HCV/HIV co-infected patients.
Monoterapija lijekom ViraferonPeg nije ispitivana u bolesnika s istodobnom infekcijom HCV-om i HIV-om.
ViraferonPeg monotherapy – Adults Dose to be administered
ViraferonPeg u monoterapiji – odrasli Doza koju treba primijeniti
ViraferonPeg pharmacodynamics were assessed in a rising single-dose trial in healthy subjects by examining changes in oral temperature, concentrations of effector proteins such as serum neopterin and 2’5’-oligoadenylate synthetase (2’5’-OAS), as well as white cell and neutrophil counts.
Farmakodinamika lijeka ViraferonPeg ocijenjena je u ispitivanju u kojemu su zdravim ispitanicima davane sve veće pojedinačne doze lijeka, i to mjerenjem promjena oralne temperature, koncentracije efektornih proteina poput serumskog neopterina i 2'5'-oligoadenilat-sintetaze (2'5'-OAS) te promjena broja leukocita i neutrofila.
ViraferonPeg plus ribavirin
ViraferonPeg s ribavirinom
ViraferonPeg strength (µg/0.5 ml)
Jačina lijeka ViraferonPeg (µg/0,5 ml)
Viral escape from maraviroc can occur via 2 routes: the selection of virus which can use CXCR4 as its entry co-receptor (CXCR4-using virus) or the selection of virus that continues to use exclusively CCR5 (CCR5-tropic virus).
Rezistencija virusa na maravirok može se razviti na dva načina: selekcijom virusa koji može koristiti CXCR4 kao ko-receptor za ulaz (virus koji koristi CXCR4) ili selekcijom virusa koji koristi samo CCR5 receptor (CCR5-tropni virus).
Viral hepatitis.
virusnog hepatitisa
Viral infection
Virusna infekcija
viral infection in the gut
virusna infekcija crijeva
Viral infection*, pharyngitis*
virusna infekcija*, faringitis
Viral infection, pharyngitis
virusna infekcija, faringitis
viral infections (including cold sores, shingles, and influenza)
virusne infekcije (uključujući herpes simpleks, herpes zoster i gripu)
Viral infections such as herpes or flu
virusne infekcije poput herpesa ili gripe
viral infections such as shingles or reactivation of other virus such as herpes in the mouth
virusne infekcije poput herpes zostera ili aktivacije drugih virusa poput herpesa u ustima
Viral infectionsa Respiratory infectionsb,* Abscessc,*
virusne infekcijea infekcije dišnog sustavab,* apscesc,
Viral load reduction (log10 copies/ml)c
Smanjenje virusnog opterećenja (log10 kopija/ml)c
Viral populations with treatment-emergent NS5A resistance-associated substitutions were generally more persistent than NS3 resistance associated substitutions.
Virusne populacije sa supstitucijama povezanima s rezistencijom u NS5A koje su nastale tijekom liječenja u pravilu su bile postojanije nego supstitucije povezane s rezistencijom u NS3.
Viral relapse rates are calculated with a denominator of patients with undetectable (or unconfirmed detectable) HCV RNA at EOT.
Stope virološkog relapsa izračunate su s nazivnikom koji predstavlja broj bolesnika s nedetektabilnom ili nepotvrđeno detektabilnom HCV RNA na završetku liječenja.
Viral relapse1
Virološki relaps1
Viral relapse3
Virološki relaps3
Viral relapse4
Virološki relaps4
Viral shedding and viral titers in lungs were also reduced, suggesting that vaccination may reduce the risk of viral transmission.
Smanjeno je i izlučivanje virusa i titar virusa u plućima, što upućuje na to da cijepljenje može smanjiti rizik od transmisije virusa.
Viral shedding and viral titers in lungs were also reduced, suggesting that vaccination may reduce the risk of viral transmission.
U plućima je smanjen titar virusa kao i širenje virusa, što ukazuje na to da cijepljenje može smanjiti rizik od transmisije virusa.
Viral shedding into the upper respiratory tract was also reduced in vaccinated animals relative to controls, suggesting a reduced risk of viral transmission.
U usporedbi s kontrolnom skupinom širenje virusa u gornje dišne puteve također je bilo smanjeno, ukazujući na smanjen rizik od prijenosa virusa.
Viral Subtype Clade B 187 (170, 204)
Podtip virusa skupine B
Viral suppression was maintained (follow-on study NUC20917) with combined therapy during the second year of treatment to week 104 with patients having continued improvement in virologic and biochemical responses.
Viralna supresija je održavana (na temelju studije NUC20917) kombiniranom terapijom tijekom druge godine terapije do 104. tjedna te se bolesnicima i virološki i biokemijski odgovor nastavio poboljšavati.
viral,
gastroenteritis,
Viramune 100 mg prolonged-release tablets
Viramune 100 mg tablete s produljenim oslobađanjem
Viramune 100 mg prolonged-release tablets are supplied in bottles with 90 prolonged- release tablets.
Viramune 100 mg tablete s produljenim oslobađanjem dostupne su u bočicama s 90 tableta s produljenim oslobađanjem.
Viramune 100 mg prolonged-release tablets Viramune 50 mg prolonged-release tablets nevirapine
Viramune 100 mg tablete s produljenim oslobađanjem Viramune 50 mg tablete s produljenim oslobađanjem nevirapin
Viramune 200 mg tablets
Viramune 200 mg tablete
Viramune 400 mg prolonged-release tablets
Viramune 400 mg tablete s produljenim oslobađanjem
Viramune 400 mg prolonged-release tablets can be taken by children if they:
Viramune 400 mg tablete s produljenim oslobađanjem mogu uzimati djeca ako:
Viramune 50 mg prolonged-release or 100 mg prolonged-release tablets can be taken by children three years of age and above.
Viramune 50 mg tablete s produljenim oslobađanjem ili 100 mg tablete s produljenim oslobađanjem mogu uzimati djeca u dobi tri godine i stariji.
viramune 50 mg prolonged-release tablets
viramune 50 mg tablete s produljenim oslobađanjem
Viramune 50 mg prolonged-release tablets are supplied in bottles with 180 prolonged- release tablets.
Viramune 50 mg tablete s produljenim oslobađanjem dostupne su u bočicama sa 180 tableta s produljenim oslobađanjem.
Viramune 50 mg prolonged-release tablets are yellow, round and biconvex.
Viramune 50 mg tablete s produljenim oslobađanjem su žute, okrugle i bikonveksne.
Viramune 50 mg prolonged-release tablets nevirapine
Viramune 50 mg tablete s produljenim oslobađanjem nevirapin
Viramune 50 mg prolonged-release tablets or 100 mg prolonged-release tablets should not be used by adults.
Odrasle osobe ne smiju primjenjivati Viramune 50 mg tablete s produljenim oslobađanjem ili 100 mg tablete s produljenim oslobađanjem.
Viramune 50 mg/5 ml oral suspension
Viramune 50 mg/5 ml oralna suspenzija
Viramune 50 mg/5 ml Oral suspension and Viramune 400 mg, 100 mg and 50 mg prolonged-release tablets
Viramune 50 mg/5 ml oralna suspenzija i Viramune 400 mg, 100 mg i 50 mg tablete s produljenim oslobađanjem
Viramune 50 mg/5 ml oral suspension nevirapine
Viramune 50 mg/5 ml oralna suspenzija nevirapin
Viramune administration above the recommended dose might increase the frequency and seriousness of skin reactions, such as Stevens-Johnson syndrome and toxic epidermal necrolysis.
Primjena Viramune u dozama višim od preporučenih može povećati učestalost i ozbiljnost kožnih reakcija, kao što su Stevens-Johnsonov sindrom i toksična epidermalna nekroliza.
Viramune can be taken with or without food.
Viramune se može uzimati s hranom ili bez nje.
Viramune contains sucrose, sorbitol, methyl parahydroxybenzoate and propyl parahydroxybenzoate
Viramune sadrži saharozu, sorbitol, metilparahidroksibenzoat i propilparahidroksibenzoat
Viramune immediate-release
Viramune s trenutnim oslob.
Viramune is also available as 200 mg tablets for older children, particularly adolescents, weighing more than 50 kg or having a body surface of more than 1.25 m2.
Viramune je također dostupan u obliku 200 mg tableta za stariju djecu, osobito adolescente, koja imaju više od 50 kg težine ili imaju tjelesnu površinu veću od 1,25 m2.
Viramune is also available as a 200 mg tablet for patients 16 years and older, or for older children, particularly adolescents, weighing 50 kg or more or whose BSA is above 1.25 m2.
Viramune je također dostupan u obliku tableta od 200 mg za bolesnike u dobi 16 i više godina starosti, osobito adolescente koji teže 50 ili više kg ili čiji je BSA (tjelesna površina) iznad 1,25 m2.
Viramune is also available as an oral suspension, tablets or as prolonged-release tablets with lower strengths.
Viramune je također dostupan u obliku oralne suspenzije, tableta ili tableta s produljenim oslobađanjem manjih jačina.
Viramune is contraindicated in patients with severe hepatic impairment (Child-Pugh C, see section 4.3).
Viramune je kontraindiciran u bolesnika s teškim jetrenim poremećajima (Child- Pugh C, vidjeti dio 4.3).
Viramune is contraindicated in patients with severe hepatic impairment (Child-Pugh C, see section 4.3).
Viramune je kontraindiciran u bolesnika s teškim jetrenim poremećajima (Child-Pugh C, vidjeti dio 4.3).
Viramune is indicated for the treatment of HIV-1 infected adults, adolescents, and children of any age.
Viramune je indiciran za liječenje odraslih osoba, adolescenata i djece bilo koje dobi inficiranih HIV- om.
Viramune is indicated in combination with other anti-retroviral medicinal products for the treatment of HIV-1 infected adolescents and children three years and above and able to swallow tablets (see section 4.2).
Viramune je indiciran u kombinaciji s drugim antiretrovirusnim lijekovima za liječenje adolescenata i djece s HIV-1 infekcijom u dobi tri i više godina koji mogu gutati tablete (vidjeti dio 4.2).
Viramune is indicated in combination with other anti-retroviral medicinal products for the treatment of HIV-1 infected adults, adolescents, and children of any age (see section 4.2).
Viramune je indiciran u kombinaciji s drugim antiretrovirusnim lijekovima za liječenje HIV-1 infekcije kod odraslih osoba, adolescenata i djece svih dobnih skupina (vidjeti dio 4.2).
Viramune is not a cure for HIV infection.
Viramune ne dovodi do izlječenja HIV infekcije.
Viramune oral suspension contains 150 mg sucrose and 162 mg sorbitol per ml of Viramune oral suspension.
Viramune oralna suspenzija sadrži 150 mg saharoze i 162 mg sorbitola u 1 ml Viramune oralne suspenzije.
Viramune prolonged-release
Viramune s produljenim oslob.
Viramune prolonged-release tablets have not been studied in patients with renal dysfunction and Viramune immediate-release should be used.
Viramune tablete s produljenim oslobađanjem nisu ispitivane na bolesnicima s disfunkcijom bubrega te se stoga primjenjuje Viramune s trenutnim oslobađanjem.
Viramune prolonged-release tablets may be dosed based on a patient’s weight or body surface area (BSA).
Viramune tablete s produljenim oslobađanjem mogu se dozirati na osnovi tjelesne težine ili tjelesne površine (BSA) bolesnika.
Viramune should be administered by physicians who are experienced in the treatment of HIV infection.
Viramune moraju primjenjivati liječnici s iskustvom u liječenju HIV-infekcija.
Viramune should be combined with at least two additional antiretroviral agents.
Viramune se kombinira s najmanje dva druga dodatna antiretrovirusna lijeka.
Viramune should not be used as the sole active antiretroviral, as monotherapy with any antiretroviral has shown to result in viral resistance.
Viramune se ne smije primjenjivati u obliku monoterapije aktivnim antiretrovirusnim lijekom, jer monoterapija bilo kojim antiretrovirusnim lijekom rezultira virusnom rezistencijom.
Viramune tablets can be taken by:
Viramune tablete mogu uzimati:
VIRBAC BELGIUM N.V.
VIRBAC Tierarzneimittel GmbH Rögen 20
VIRBAC ESPAŇA S.A.
VIRBAC S.A.
VIRBAC S.A.
171 21 Solna
VIRBAC S.A.
Box 1027,
VIRBAC S.A.
Norge
VIRBAC S.A.
Pärnasalu 31
VIRBAC Österreich GmbH Hildebrandgasse 27
Virbac Norge c/o Premium Pet Products Vollaveien 20 A
Viread 123 mg [outer packaging only]
Viread 123 mg [samo na vanjskom pakiranju]
Viread 123 mg film-coated tablets
Viread 123 mg filmom obložene tablete
Viread 123 mg film-coated tablets
Viread 123 mg filmom obložene tablete tenofovirdizoproksil
Viread 123 mg film-coated tablets contain lactose monohydrate.
Viread 123 mg filmom obložene tablete sadrži laktozu hidrat.
Viread 123 mg film-coated tablets should be taken once daily, orally with food.
Viread 123 mg filmom obložene tablete potrebno je uzimati peroralno s hranom, jedanput na dan.